Our People
Stefan Ochiana, Ph.D.

Stefan Ochiana, Ph.D.

202-970-3034
sochiana@fenwick.com
Associate
Intellectual Property
Office

Washington, DC

Stefan
Ochiana, Ph.D.

Stefan
Ochiana, Ph.D.

Stefan
Ochiana, Ph.D.

Associate
Intellectual Property
Office

Washington, DC

Industries
Education & Admissions

Ph.D., Organic Chemistry, Northeastern University

J.D., George Washington University Law School

B.S., Biochemistry, Saint Vincent College

Admitted to practice in the District of Columbia, Massachusetts, and Maryland

Admitted to practice before the U.S. Court of Appeals for the Federal Circuit

Registered to practice before the U.S. Patent and Trademark Office

Languages

Fluent in Romanian

Stefan prosecutes and provides strategic counseling on U.S. and foreign patent portfolios in the chemical and pharmaceutical industries. His experience also includes assisting with Abbreviated New Drug Application (ANDA) litigations under the Hatch-Waxman Act, inter partes review (IPR) proceedings before the U.S. Patent and Trademark Office (USPTO), and disputes in district courts across the country.

Prior to joining Fenwick, Stefan worked as an associate for a large intellectual property firm, where his practice focused on strategic counseling, prosecution, and patent litigation, primarily in the chemical and pharmaceutical fields.

Stefan also completed a post-doctoral training at Memorial Sloan Kettering Cancer Center. His work included several projects aimed at the discovery and development of heat shock protein 90 (Hsp90), Hsp70, glucose-regulated protein 94 inhibitors, and the design and synthesis of chemical probes for the biological evaluation of these targets.

Stefan’s graduate dissertation research focused on the design, synthesis, and evaluation of human aurora kinase and phosphodiesterase inhibitors for anti-trypanosomal drug discovery via target repurposing. Stefan has a wide range of technical experience, including the areas of organic and medicinal chemistry, computational chemistry, drug delivery, preclinical drug development, and chemical biology. He has authored or co-authored eighteen journal papers and a book chapter, presented his research at thirteen national and local conferences, and is a co-inventor on many patent applications related to his postdoctoral work.

Read more

  • Royalty Pharma and Pharmakon Advisors on IP diligence in their agreements to supply up to $375 million in funding to Geron Corporation
  • Royalty Pharma on IP diligence in its up to €128.8 million ($140 million) royalty monetization agreement with BRAIN Biotech AG
  • Royalty Pharma on IP diligence in its $905 million royalty acquisition agreement with Agios Pharmaceuticals
  • Pharmakon Advisors on IP diligence in its $400 million non-dilutive loan agreement with Novocure
  • Pharmakon Advisors on IP diligence in its $200 million non-dilutive loan agreement with Tarsus Pharmaceuticals
  • Samsara BioCapital on IP diligence in its investment in Alumis’ $259 million Series C financing
  • Royalty Pharma on IP diligence regarding its up to $125 million R&D support agreement with Teva relating to Teva's olanzapine LAI (TEV-'749)
  • Royalty Pharma on IP diligence regarding its up to $1.5 billion purchase of royalties for Roche’s Evrysdi, an orally administered survival motor neuron (SMN2) medication for the treatment of spinal muscular atrophy, from PTC Therapeutics.
  • Castle Retail in patent litigation brought by Hawk Technology Systems on appeal. The Federal Circuit affirmed a Western District of Tennessee decision granting Castle Retail's motion to dismiss and invalidating Hawk's patent claims related to video surveillance technology.
  • Pharmacyclics LLC in inter partes review challenge related to Imbruvica® (ibrutinib) for the treatment of chronic graft versus host disease.

* Includes experience from a prior firm

  • Royalty Pharma and Pharmakon Advisors on IP diligence in their agreements to supply up to $375 million in funding to Geron Corporation
  • Royalty Pharma on IP diligence in its up to €128.8 million ($140 million) royalty monetization agreement with BRAIN Biotech AG
  • Royalty Pharma on IP diligence in its $905 million royalty acquisition agreement with Agios Pharmaceuticals
  • Pharmakon Advisors on IP diligence in its $400 million non-dilutive loan agreement with Novocure
  • Pharmakon Advisors on IP diligence in its $200 million non-dilutive loan agreement with Tarsus Pharmaceuticals
  • Samsara BioCapital on IP diligence in its investment in Alumis’ $259 million Series C financing
  • Royalty Pharma on IP diligence regarding its up to $125 million R&D support agreement with Teva relating to Teva's olanzapine LAI (TEV-'749)
  • Royalty Pharma on IP diligence regarding its up to $1.5 billion purchase of royalties for Roche’s Evrysdi, an orally administered survival motor neuron (SMN2) medication for the treatment of spinal muscular atrophy, from PTC Therapeutics.
  • Castle Retail in patent litigation brought by Hawk Technology Systems on appeal. The Federal Circuit affirmed a Western District of Tennessee decision granting Castle Retail's motion to dismiss and invalidating Hawk's patent claims related to video surveillance technology.
  • Pharmacyclics LLC in inter partes review challenge related to Imbruvica® (ibrutinib) for the treatment of chronic graft versus host disease.

* Includes experience from a prior firm